The 20 Best Pancreatoblastoma Doctors Near Me in Ypsilanti, MI

Dr. Zalupski is an Professor of Medicine in the division of Medical Oncology at the UMMC. He completed medical school, an internal medicine residency and a medical oncology fellowship at Wayne State University in Detroit. Dr. Zalupski's clinical and research interest is in experimental therapeutics of gastrointestinal malignancies and sarcomas. He also serves as the medical director of the Multidisciplinary Pancreatic Cancer Clinic. Dr. Zalupski is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Neuroendocrine Tumor, Familial Pancreatic Cancer, and Pancreaticoduodenectomy. Dr. Zalupski is board certified in Internal Medicine and Medical Oncology.

Jerome Winegarden is a Hematologist practicing medicine in Ypsilanti, Michigan. Dr. Winegarden is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Colorectal Cancer, Familial Colorectal Cancer, and Chronic Lymphocytic Leukemia (CLL).

Thomas Regenbogen is a Hematologist practicing medicine in Ypsilanti, Michigan. Dr. Regenbogen is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Anal Cancer, and Pleuropulmonary Blastoma.

Carolyn Carrera is a Hematologist practicing medicine in Ypsilanti, Michigan. Dr. Carrera is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, and Angiosarcoma.

Tareq Baghdadi is a Hematologist practicing medicine in Ypsilanti, Michigan. Dr. Baghdadi is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 40 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, Tissue Biopsy, and Bone Marrow Aspiration.

Walter Sahijdak is a Radiation Oncologist practicing medicine in Ypsilanti, Michigan. Dr. Sahijdak is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Pleuropulmonary Blastoma, and Breast Cancer.

Eva Bieniek is a Radiation Oncologist practicing medicine in Ypsilanti, Michigan. Dr. Bieniek is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Posterior Fossa Tumor, Lung Cancer, Pleuropulmonary Blastoma, and Endometrial Cancer.

Richard Cattaneo is a Radiation Oncologist practicing medicine in Ypsilanti, Michigan. Dr. Cattaneo is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET).

Samir Narayan is a Radiation Oncologist practicing medicine in Ypsilanti, Michigan. Dr. Narayan is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Familial Prostate Cancer, and Posterior Fossa Tumor.

Marie-adele Kress is a Radiation Oncologist practicing medicine in Ypsilanti, Michigan. She has been practicing medicine for over 17 years. Dr. Kress is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Laryngeal Cancer, Prostate Cancer, and Pleuropulmonary Blastoma.

Edward Kreske is a General Surgeon practicing medicine in Ypsilanti, Michigan. Dr. Kreske is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Familial Colorectal Cancer, Small Bowel Resection, and Pancreatectomy.

Niklas Mackler is a Hematologist practicing medicine in Ypsilanti, Michigan. Dr. Mackler is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Lung Cancer.

Erik Carson is a Hematologist practicing medicine in Ypsilanti, Michigan. Dr. Carson is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Breast Cancer, and Paget Disease of the Breast.

Philip Stella is an Oncologist practicing medicine in Ypsilanti, Michigan. Dr. Stella is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Colorectal Cancer, Pancreatic Cancer, and Pleuropulmonary Blastoma.

Thomas Enzler, MD PhD, is an Assistant Professor in the Division of Hematology and Oncology. He received his Master of Science from ETH Zurich and his Medical Degree from University of Basel, Switzerland. After completion of residency in Internal Medicine at University Hospitals of Zurich and Basel, Dr. Enzler did a research fellowship at the Dana Farber Cancer Institute, Harvard Medical School, Boston. There, he worked on projects focusing on tumor immune surveillance and his work resulted in several publications and in a PhD ‘magna cum laude’ in Biochemistry/Immunology (Harvard Medical School Boston/Max Delbrueck Center Berlin). He then moved to University of California San Diego to study signaling pathways of cancer cells and immune cells. While there, he successfully obtained ECFMG certification prior to doing clinic and laboratory research at Stanford University. From California Dr. Enzler went to Germany to do a Hematology and Oncology fellowship at University of Goettingen and he received board certification in both in Germany and in Switzerland. Dr. Enzler decided to return to the U.S. and completed U.S. residency in Internal Medicine at University of Arizona in Tucson. Following U.S. residency training, Dr. Enzler completed fellowship in Hematology and Oncology at Columbia University Medical Center, New York, where he worked on several research projects on gastrointestinal cancers. Dr. Enzler is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Ductal Adenocarcinoma. Dr. Enzler is board certified in Internal Medicine, Medical Oncology, and Hematology.

Dr. Bednar is a faculty member in the Department of Surgery at the University of Michigan.His undergraduate training was done at Princeton University, where he graduated with a Bachelor of Arts degree in molecular biology in 2000. After that he transitioned to the Lewis Katz School of Medicine of Temple University in Philadelphia. Dr. Bednar spent seven years in the combined MD/PhD program where he earned an MD and PhD in Microbiology and Immunology in the laboratory of Dr. Thomas Rogers. His dissertation thesis focused on how human monocytes respond to the complex external environment present during an infection or inflammatory state. After the completion of his medical training he was accepted to the General Surgery Residency program at the University of Michigan. During his time in Ann Arbor, he also spent two years in a postdoctoral research fellowship in the laboratories of Dr. Diane Simeone and Dr. Marina Pasca di Magliano. During Dr. Bednar's research time, he studied the basic biology of pancreatic cancer, which led to his evolving interest in cancer patient care. He finished his clinical training in the Complex General Surgical Oncology Fellowship program at the University of Pittsburgh and was recruited back to the University of Michigan to become a part of the pancreatic cancer research group that has developed here in the past decade. Dr. Bednar is a board-certified general surgeon and currently undergoing board certification for additional specialization of Complex General Surgical Oncology. He is also BLS/ACLS certified.Dr. Bednar's clinical and research effort up to now has been recognized through several awards. He received the Dr. Herman Brown Award for Excellence in the Study of the Art and Science of Surgery from the Department of Surgery, Lewis Katz School of Medicine, Temple University as a recognition for his care of the surgical patients and his research work while he was a medical student. Dr. Bednar's work on pancreatic cancer was recognized and supported by an American College of Surgeons Research Fellowship. He also received the Robert V. Danto Cancer Research Award from the Michigan chapter of the American College of Surgeons for his postdoctoral research work. His work was chosen to be presented at the Owen Wangensteen Surgical Forum during the annual American College of Surgeons meeting in 2013 and received the Best Oral Presentation award at the 24th Annual Moses Gunn Research Conference of the Department of Surgery at the University of Michigan in 2012.Clinical Specialization:Dr. Bednar is a practicing general and oncologic surgeon. His practice encompasses the full gamut of general surgery and complex abdominal and soft tissue surgical oncology. During his fellowship training, he also received specific instruction on the DaVinci robotic surgery platform and hope to continue to support the already-established efforts in this arena. Dr. Bednar is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Neuroendocrine Tumor, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Bednar is board certified in Surgery and Complex General Surgical Oncology.

Dr. Daniel Chang is a nationally and internationally recognized expert in radiotherapy for GI malignancies. His primary research interest is in advanced radiotherapy techniques, primarily with stereotactic body radiotherapy (SBRT). He has led several studies investigating and establishing the efficacy and safety for SBRT for these diseases for liver and pancreatic tumors. His other research interests include normal tissue tolerances, quality of life after radiotherapy, and combining radiotherapy with targeted agents. In addition, he has a strong interest in the use of radiotherapy, particularly in combination with systemic agents, in patients with metastatic disease. Another area of interest is in health care utilization for patients with metastatic disease and using machine learning and other approaches to optimize care during the end-of-life period.Dr. Chang is interested in developing novel modalities and technologies for delivering radiotherapy. He previously led the FDA trial that led to approval of PET-guided radiotherapy, which in broader terms, is called Biology-guided radiotherapy. In addition, he has experience with MR-guided radiotherapy, and he is interested in exploring the role of particle therapy and heave ion radiotherapy.Dr. Chang received his MD from Wayne State University in 2002 and completed his residency in Radiation Oncology at the University of Florida in Gainesville, Florida in 2007. He then joined the Department of Radiation Oncology at Stanford University from 2007-2022, having previously served as residency program director from 2012-2017 and the Vice Chair of Clinical Operations from 2017-2022 where he was also the Sue and Bob McCollum Professor in Radiation Oncology.Dr. Chang is a member of the American Society of Radiation Oncology (ASTRO), American Radium Society (ARS), and the American Society of Clinical Oncology (ASCO). He serves on the scientific committee for ASTRO, ASCO, and GI ASCO. He has authored or co-authored over 190 peer-reviewed publications for journals including Journal of Clinical Oncology, Journal of the National Cancer Institute, Clinical Cancer Research, Radiology, International Journal of Radiation Oncology, Biology, and Physics, Radiotherapy and Oncology, and Cancer. He served as the senior editor for the GI section of the International Journal of Radiation Oncology, Biology, and Physics from 2013-2017 and is currently on the editorial board for Practical Radiation Oncologysince 2020. He served on the Hepatobiliary Panel for the National Cancer Comprehensive Network (NCCN) guidelines from 2013-2022, helping to shape national guidelines for the work-up, diagnosis, and treatment of patients with hepatobiliary cancers. He is currently the track chair for the GI track for the ASTRO Annual Meeting Scientific Committee. He also serves on the Education Committee for the Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Track for the ASCO annual meeting starting in 2023. Dr. Chang is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Anal Cancer, Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), and Familial Pancreatic Cancer. Dr. Chang is board certified in Radiation Oncology.

Dr. Ferguson is a Clinical Assistant Professor of Surgery in the Division of Hepato-pancreato-biliary Surgery. Following undergraduate studies in Molecular & Integrative Physiology at the University of Illinois, he earned an MD and a PhD in Cancer Biology at the University of Chicago. He completed a general surgery residency at the University of Chicago, where he served as an administrative chief resident and completed a medical education fellowship, followed by a clinical fellowship in complex general surgical oncology at Memorial Sloan Kettering Cancer Center. He is board-certified in general surgery and complex general surgical oncology.He has won numerous teaching awards at every stage of his career. He is the co-editor of Difficult Decisions in Surgical Oncology—An Evidence-Based Approach. He is active in the American College of Surgeons, Society of Surgical Oncology, Americas Hepato-Pancreato-Biliary Association, and Association for Surgical Education.Clinical Specialization: Dr. Ferguson's clinical expertise is in the management of cancers and premalignant conditions of the pancreas, liver, bile ducts, gallbladder, and stomach. Dr. Ferguson is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Bile Duct Cysts, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Ferguson is board certified in Surgery and Complex General Surgical Oncology.

Dr. Cuneo grew up in Northern California. He studied Biological and Environmental Engineering at Cornell University in Ithaca, NY. Dr. Cuneo received his Doctor of Medicine degree from Vanderbilt University School of Medicine in 2007 and completed an internship there in 2008. In 2008 he started his residency in Radiation Oncology at Duke University Medical Center. Dr. Cuneo has been an Assistant Professor in the Department of Radiation Oncology at the University of Michigan since 2012. Dr. Cuneo is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 35 other conditions, according to our data. His clinical expertise encompasses Anal Cancer, Pancreatic Cancer, Liposarcoma, Liver Cancer, and Pancreaticoduodenectomy. Dr. Cuneo is board certified in Radiation Oncology.

Dr. Sahai is the Leader of the Gastrointestinal Medical Oncology Section and Associate Professor in the Division of Hematology-Oncology, Department of Internal Medicine. Dr. Sahai is also a member of the University of Michigan Rogel Cancer Center and Director of Tumor Response Assessment Core.Dr. Sahai attended medical school at the Government Medical College at Amritsar with the Baba Farid University of Health Science in India. He then completed his Masters in Clinical Epidemiology at Harvard School of Public Health followed by Internal Medicine residency training at University of Pittsburgh where he met his wife. He completed his fellowship in Hematology-Oncology at Northwestern University where he also served as the Chief Fellow. Subsequently, Dr. Sahai joined University of Michigan as Assistant Professor in Internal Medicine in 2013.Dr. Sahai is a clinician-scientist who sees patients within the Multidisciplinary Pancreatic and Liver Tumor programs. As a clinical investigator he is the Principal Investigator on several investigator-initiated clinical trials open across the U.S. His translational research program leverages the pancreaticobiliary cancer biobanks that he directs for the therapeutic investigation of novel compounds in patient-derived cell lines and xenograft models to help develop novel phase 1/2 investigator-initiated clinical trials. Dr. Sahai is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Familial Pancreatic Cancer, and Neuroendocrine Tumor.